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Resting-State Functional Connectivity Disruption
As a Pathological Biomarker in Autosomal Dominant
Alzheimer Disease
Robert X. Smith,1 Jeremy F. Strain,1 Aaron Tanenbaum,1 Anne M. Fagan,1,2 Jason Hassenstab,1
Eric McDade,1 Suzanne E. Schindler,1 Brian A. Gordon,2,3 Chengjie Xiong,4 Jasmeer Chhatwal,5
Clifford Jack Jr.,6 Celeste Karch,2,7 Sarah Berman,8 Jared R. Brosch,9 James J. Lah,10
Adam M. Brickman,11 David M. Cash,12 Nick C. Fox,12 Neill R. Graff-Radford,13 Johannes Levin,14
James Noble,11 David M. Holtzman,1,2 Colin L. Masters,15 Martin R. Farlow,9 Christoph Laske,16
Peter R. Schofield,17 Daniel S. Marcus,3 John C. Morris,1,2 Tammie L.S. Benzinger,2,3
Randall J. Bateman,1,2 and Beau M. Ances,1,2; for the DIAN Network

Abstract

Aim: Identify a global resting-state functional connectivity (gFC) signature in mutation carriers (MC) from the
Dominantly Inherited Alzheimer Network (DIAN). Assess the gFC with regard to amyloid (A), tau (T), and neurodegeneration (N) biomarkers, and estimated years to symptom onset (EYO).
Introduction: Cross-sectional measures were assessed in MC (n = 171) and mutation noncarrier (NC) (n = 70)
participants. A functional connectivity (FC) matrix that encompassed multiple resting-state networks was computed for each participant.
Methods: A global FC was compiled as a single index indicating FC strength. The gFC signature was modeled as
a nonlinear function of EYO. The gFC was linearly associated with other biomarkers used for assessing the
AT(N) framework, including cerebrospinal fluid (CSF), positron emission tomography (PET) molecular biomarkers, and structural magnetic resonance imaging.
Results: The gFC was reduced in MC compared with NC participants. When MC participants were differentiated
by clinical dementia rating (CDR), the gFC was significantly decreased in MC CDR >0 (demented) compared
with either MC CDR 0 (cognitively normal) or NC participants. The gFC varied nonlinearly with EYO and initially decreased at EYO = 24 years, followed by a stable period followed by a further decline near EYO = 0
years. Irrespective of EYO, a lower gFC associated with values of amyloid PET, CSF Ab1–42, CSF p-tau,
CSF t-tau, 18F-fluorodeoxyglucose, and hippocampal volume.
Conclusions: The gFC correlated with biomarkers used for defining the AT(N) framework. A biphasic change in
the gFC suggested early changes associated with CSF amyloid and later changes associated with hippocampal
volume.
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Impact Statement

This project focused on creating and evaluating a global functional connectivity (FC) signature that may serve as an outcome
measure in clinical trials. This global FC signature encompassed multiple resting-state networks that included both inter- and
intranetworks. Prior studies that focus on a single network may overlook important changes seen within and between networks. Our analysis is a logical progression from previous work that demonstrated that intra- and internetwork brain connections across multiple networks were affected with progression to cognitive impairment in autosomal dominant Alzheimer
disease. This work revealed that FC disruption exhibits a nonlinear time course that was consistent with proposed biomarker
models.

Introduction

A

lzheimer disease (AD) is the leading cause of dementia in the United States. The occurrence of AD has been
linked with b-amyloid (Ab) peptide aggregating into plaques
in the brain (Burdick et al., 1992). Ab levels vary naturally
following a circadian rhythm (Kang et al., 2009) and are associated with neuronal excitability (Palop et al., 2007). Excess
production from neuronal hyperexcitability may underlie plaque formation (Mattsson et al., 2016; Palop et al., 2007). The
amyloid cascade hypothesis (Mosconi., 2005) proposes that
accumulation of Ab plaques results in neurotoxic effects
that are associated with tau accumulation and neurodegeneration culminating in cognitive dysfunction (as assessed by
the clinical dementia rating [CDR]) (Bateman et al., 2012).
Autosomal dominant Alzheimer disease (ADAD) is
caused by *100% penetrant mutations in genes that encode
for the amyloid precursor protein (APP) (Bateman et al.,
2011; Ryman et al., 2014; Schindler and Fagan, 2015) or
gamma-secretase components, presenilin (PSEN) 1 and
PSEN2. The ability to estimate when mutation-positive (mutation carriers [MC]) carriers will develop cognitive changes
allows for modeling of disease based on estimated years to
symptom onset (EYO). ADAD typically occurs at an earlier
age compared with late-onset AD (LOAD) (Dubois et al.,
2016; Frisoni, 2012; Smailagic et al., 2014) and is not associated with age-related comorbidities.
Pathologic changes start decades before clinical symptoms
manifest in ADAD (Bateman et al., 2012). Recently, a set of
biomarker criteria has been proposed to stage LOAD disease
progression ( Jack et al., 2012). This model describes that the
earliest changes involve amyloid accumulation (A), followed
by tau (T) deposition, and eventually neurodegeneration (N)
that lead to cognitive dysfunction (Berti et al., 2010; Ewers
et al., 2011; Fennema-Notestine et al., 2009; Frisoni et al.,
2010; Klunk et al., 2004; Mosconi et al., 2010; Smailagic
et al., 2015; Vlassenko et al., 2012).
Changes in amyloid biomarkers, such as cerebrospinal
fluid (CSF) Ab1–42 and Pittsburgh compound B (PiB) amyloid positron emission tomography (PET), have been observed *15–20 years before symptom onset in ADAD
(Bateman et al., 2012; Berti et al., 2010; Brier et al., 2016;
Forsberg et al., 2008; Gordon et al., 2018; McDade et al.,
2018). Tau (T) biomarkers, such as CSF phosphorylated
tau181 (p-tau181) (Schindler and Fagan, 2015), change
*10–15 years before symptom onset in ADAD.

Neurodegeneration (N) biomarkers, such as CSF total tau
(t-tau) (McDade et al., 2018; Schindler and Fagan, 2015)
18F-fluorodeoxyglucose (FDG) PET, a measure of glucose
metabolism (Mosconi., 2005), and magnetic resonance imaging (MRI) measurements of hippocampal volume (Bateman
et al., 2012; Bobinski et al., 2000; Gordon et al., 2018;
McDade et al., 2018; Zarow et al., 2005), change at *5–10
years before EYO. CSF-based measures are sensitive to global
levels of amyloid accumulation and tau deposition, but lack
information pertaining to what brain regions are affected.
Imaging, on the contrary, provides spatially detailed information regarding impacted brain regions. In fact, PET imaging has
revealed that amyloid may accumulate in a pattern of brain regions distributed across multiple functional brain networks
(Thomas et al., 2014). This has led some to hypothesize that
the pathological spread of disease through the brain occurs via
brain networks (Forsberg et al., 2008; Thomas et al., 2014).
However, a gap persists regarding when changes in brain networks occur with respect to AT(N) biomarkers in ADAD.
Resting-state functional connectivity (FC) noninvasively
measures the association of signaling among brain regions
and can be used to identify resting-state networks (RSNs)
(Franzmeier et al., 2020). The inter-relationships among
RSNs is sensitive to neuronal dysfunction and is associated
with the degree of cognitive impairment (Frisoni et al., 2010;
Frisoni., 2012; Frost and Diamond, 2010). A reduction in
both intra- and internetwork FC occurs in ADAD (Gholipour
et al., 2008). Global metrics of amyloid and tau accumulation
aggregate spatially selective patterns for increased sensitivity.
Similarly, a global FC signature can be derived from a combination of changes in intra- and internetworks that spans multiple RSNs (Power et al., 2012; Su et al., 2015). It remains
important to know where changes in this global FC signature
occur in the temporal progression of ADAD.
The purpose of this study is to evaluate the role of FC
within the AT(N) framework in ADAD. Prior work has focused on select FC network differences, however, we use a
data reduction strategy to compile information across multiple intra- and internetwork connections into a single
global FC signature of ADAD. We assess FC strength
based on a global FC signature between noncarriers (NC),
MC asymptomatic (CDR 0), and MC symptomatic (CDR
>0). We also evaluate the relationship between the global
FC signature and established biomarkers that comprise
the AT(N) framework and model the global FC signature
as a function of EYO.

FUNCTIONAL CONNECTIVITY DISRUPTION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE
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Participant characteristics

The cohort consisted of 171 individuals with ADAD mutations (MC) and 104 individuals from ADAD families who
were genetically at-risk for inheriting the mutation but were
not carriers (NC). All participants were enrolled in the international Dominantly Inherited Alzheimer Network (DIAN)
and extracted from Data Freeze 11. Inclusion into this current analysis required that participants complete a general
physical (including neurologic) examination, health and
medication history, clinical assessment for dementia (Gordon et al., 2018), biochemical analysis, neuroimaging acquisition on only 3T Siemens Tim Trio scanners (Erlangen,
Germany), and successful pass all quality control criteria
(e.g., reduced motion during neuroimaging acquisition).
All participants or their representatives provided written informed consent that was in accordance with the Washington
University Institutional Review Boards or their respective institutions provided approval.
Clinical dementia rating

Experienced clinicians conducted semistructured interviews of each participant and a knowledgeable collateral
source. The CDR was used to evaluate the degree of impairment (Morris, 1993). A score of CDR 0 indicates cognitively
normal, CDR 0.5 corresponds to very mild dementia, and
CDR ‡1 specifies mild to moderate dementia. Participants
with a score of CDR >0 had a clinical diagnosis of AD dementia using previously described criteria (Greicius et al., 2003).
EYO estimation

Parent age at symptomatic onset was determined from
semistructured interviews with the participant, a knowledgeable collateral source, and/or other informants familiar with
the parental history of disease. The age at onset of the affected parent was determined by estimating the time of
onset of consistent symptoms (e.g., memory/cognition,
motor, or behavior) (Ryman et al., 2014). The EYO for
each individual from DIAN was defined as age at testing
minus the age at symptom onset for that individual’s affected
parent (Bateman et al., 2011).
Biochemical analyses

A lumbar puncture was performed in the morning under
fasting conditions to obtain CSF using previously described
methods (Bateman et al., 2012). Samples were shipped on
dry ice to the DIAN biomarker core laboratory. CSF concentrations of Ab1–42, t-tau, and phosphorylated tau181 (p-tau181)
were measured by immunoassay (INNOTEST Ab1–42 and
INNO-BIA AlzBio3, Innogenetics). All values met qualitycontrol standards, including a coefficient of variation of
25% or less and kit ‘‘controls’’ that were within the expected
range as defined by the manufacturer. Measurement consistency between plates of a common sample was included in
each run.
Imaging

MRI data from only 3T Siemens Tim Trio scanners
(Erlangen, Germany) were analyzed. Scanners were cali-
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brated and used similar protocols. Structural images were acquired using the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) protocol. T1-weighted scans were automatically segmented into regions of interest according to
the Desikan atlas through FreeSurfer (Martinos Center for
Biomedical Imaging, Charlestown, MA). Blood oxygen
level-dependent (BOLD) FC was also acquired using previously described methods (Thomas et al., 2014). During the
BOLD FC scans, participants were instructed to remain
still with their eyes open and not fall asleep.
PET imaging was performed using FDG to measure glucose metabolism and PiB to measure amyloid load. PET imaging analyses were performed using a previously described
PET Unified Pipeline (Su et al., 2013). Data from the 40- to
70-min postinjection window for PiB and 40- to 60-min window for FDG were converted to standardized uptake value
ratios (SUVR) in the defined regions of interest using the cerebellar cortex as a reference region (Mintun et al., 2006).
Partial volume correction was performed with a regional
spread function (Su et al., 2015) that uses a geometric transfer matrix technique (Rousset et al., 2008). Global Ab was
summarized as the average SUVR for the precuneus, lateral
temporal, gyrus rectus, and prefrontal regions that have previously been shown to delineate AD from cognitively normal
controls (Su et al., 2013). FDG from the precuneus was utilized as changes in this region are reliable and occur early in
DIAN participants (Benzinger et al., 2013; Gordon et al.,
2018; McDade et al., 2018).
FC preprocessing

BOLD FC preprocessing followed previously described
methods (Brier et al., 2012, 2016; Thomas et al., 2014),
including correction of odd versus even slice intensity differences attributable to interleaved acquisition and compensation for head movement within and across runs.
Intensity inhomogeneity was corrected using FSL FAST
(Zhang et al., 2001) followed by intensity normalization to
obtain a whole-brain mode value of 1000. Echoplanar imaging (EPI) distortion due to magnetization inhomogeneity was
corrected using a mean field map (Gholipour et al., 2008).
Atlas transformation was computed by registering the EPI
mean image to an atlas-representative template via the MPRAGE (EPI ! MP-RAGE ! template). The template was
generated from a separate cohort of 12 cognitively normal individuals. Compensation for head motion, distortion correction, and atlas transformation were sequentially combined to
generate a volumetric time series that was resampled in
3mm3 atlas space.
Frames corrupted by excessive head motion were identified on the basis of both DVARS and frame displacement
(FD) measures (Brier et al., 2014). In greater detail, the
DVARS criterion was 0.9% root mean square of the frameto-frame signal change from the entire brain (Afyouni Nichols, 2018; Power et al., 2012). The FD criterion was 0.3 mm.
Frames were censored if either criterion was exceeded. The
time series were band-pass filtered to retain frequencies between 0.005 and 0.1 Hz. For purposes of filtering, only a linear interpolation was applied over censored frames.
Censored frames were excluded from all subsequent steps.
Denoising was accomplished using a CompCor-like strategy (Behzadi et al., 2007). In brief, nuisance regressors were
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derived from three compartments (white matter, ventricles,
and the extra-axial space) and then dimensionality reduced
to create a matrix for singular value decomposition (SVD).
White matter and ventricle masks were segmented in each
individual using FreeSurfer 5.3 (Fischl, 2012) and spatially
resampled to register with the FC data. Time series also
were extracted from high-variance voxels (temporal standard deviation >2.5% relative to the whole-brain mode)
in the extra-axial space (excluding the eyes). Nuisance regressors were derived from white matter, ventricles, and
the extra-axial space. The final set of nuisance regressors
included six parameters derived from rigid body headmotion correction, the global signal (GS) averaged over
the (FreeSurfer-segmented) brain, and the GS temporal derivative. The preprocessed time series was nonlinearly
warped to Montreal Neurological Institute (MNI) 152
space (3 mm3 voxels) space using FNIRT (Andersson
et al., 2010; Jenkinson et al., 2002; Smith et al., 2004;
Woolrich et al., 2009).
FC postprocessing

A putative set of 246 functional regions-of-interest (ROIs)
were organized into 12 RSNs that included the sensorimotor
(SM), sensorimotor-lateral (SMlat), cingulo-opercular (CO),
auditory (AUD), ventral attention (VAN), visual (VIS),
salience (SAL), default mode network (DMN), memory
(MEM), dorsal attention (DAN), subcortical (SUB), and
frontoparietal (FP) (Rousset et al., 2008). ROIs were defined
as 10-mm-diameter spheres whose center coordinates were
in MNI atlas space (Power et al., 2011). All ROIs were dis-
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tinct and occupied unique voxels. A 246 · 246 FC matrix was
obtained for each individual as follows. First, the preprocessed FC data were transformed on to the MNI atlas. Second, the mean time series was computed within each ROI
excluding the censored frames. The pairwise correlation
between all ROI time series was then derived. Correlation
values were Fisher transformed for normality. The mean
246 · 246 FC matrix across all participants is shown in
Figure 1 (left). We used each ROI’s RSN designation
(Power et al., 2011) to compute the average intra- and internetwork correlation reducing the FC to a 12 · 12 matrix. FC
values along the diagonal blocks represent intra-RSN correlations, and values in the off diagonal blocks represent interRSN correlations. The mean 12 · 12 FC matrix across all
participants is shown in Figure 1 (middle).
FC principal component analysis

Data reduction was performed to isolate a global FC signature metric of global FC changes (Smith et al., 2018; Su
et al., 2015). The intra- and internetwork pattern of FC values
from each participant was compiled, and a single global
FC signature was selected. Specifically, the 12 intranetwork
and 12 · (12  1)=2 = 66 internetwork averages (total of
12 þ 66 = 78) were compiled from all participants (n = 275)
into a single 275 · 78 matrix. The principal component analysis (PCA) of this matrix was performed by SVD. PCA is a
multivariate analysis that reveals internal data organization
and its variance. This PCA revealed distinct FC patterns of
intra- and internetwork averages across all RSNs. Each pattern comprised weights describing the influence from each

FIG. 1. PCA reveals a distributed pattern of FC changes across cortical and subcortical RSNs. Left: The mean FC matrix
across all participants. An FC matrix from 248 regions of interest was computed for each participant. Positive correlations are
shown in the upper triangle, and negatives are shown in the bottom triangle. Notched black lines on the top and to the right
indicate RSNs. The black box outline is a visual aid highlighting the intranetwork FC values of the DMN. Middle: The mean
FC-composite matrix across all participants. For each participant, an FC-composite matrix was generated by computing the
mean intra- and internetwork FC matrix values (total of 78) for all 12 RSNs. Here the black box highlights the mean intranetwork FC value of the DMN. Right: The global FC signature is derived from the primary PCA pattern and reflects positively and negatively weighted mean FC-composite values. The strongest positive weights include the SM, SMlat, CO, AUD,
VIS, and MEM. The strongest negative weights included the FP, MEM, DAN, and DMN. The black box outline highlights
the weight of the mean intranetwork FC value of the DMN. AUD, auditory; CO, cingulo-opercular; DAN, dorsal attention;
DMN, default mode network; FC, functional connectivity; FP, frontoparietal; MEM, memory; PCA, principal component
analysis; RSNs, resting-state networks; SAL, salience; SM, sensorimotor; SMlat, sensorimotor-lateral; SUB, subcortical;
VAN, ventral attention; VIS, visual. Color images are available online.
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of the 78 intra- and internetwork FC composites on that pattern. The magnitude of a given weight reflects the strength
of influence, while the sign, positive or negative, indicates
whether the corresponding intra- or internetwork FC composite tends to increase or decrease, respectively, across
participants. Each pattern was also accompanied by a set
of scores that represented its association with each participant’s pattern of FC values. The variability of these scores
related to the total variability of FC values among participants. A low score indicates that the primary pattern is
weakly present or absent from a participant. This implicates
a strong deviation from, or decline in, the network connectivity specified by the primary pattern. The primary pattern
that captured the largest percentage of total interindividual
FC variance (21%) was designated the global FC signature
for ADAD (Fig. 1, right). The same data reduction was applied to NC participants. The primary pattern from NC was
very similar to the pattern computed for all participants, indicating that patient characteristics (abnormal levels of
Ab42, tau, and neurodegeneration) are not strong factors
in determining the primary pattern.
EYO modeling
Global FC signature versus RSN. We compared the abilities of the global FC signature and intranetwork values of
the 12 RSNs included in this study to, separately, predict
EYO using a leave-one-out cross-validation. Specifically,
for each FC metric:

1. FC and EYO data were split into two sets: train and
test. The training set comprised data from N  1
mutation-positive participants, and a test set comprised
data from a single mutation-positive participant.
2. A linear predictive model was computed using the
training set:
EYOtrain = b0 þ b1 FCtrain
3. The linear model (i.e., coefficients b0 and b1 ) was used
to predict EYO of the test set:
EYOpred = b0 þ b1 FCtest
4. The error in EYO was computed:
EYOerr = EYOtest  EYOpred
5. Steps 1–4 were repeated such that the FC data for each
mutation-positive participant were used in the test set.
6. The sum of squares (SS) was computed for both EYOerr
and EYO:
SSerr = +ðEYOerr Þ2
SSEYO = +ðEYOÞ2
7. The coefficient of determination (R2), the proportion of
the variance in actual EYO that is predictable from the
FC, was computed:
R2 = 1 

SSerr
SSEYO
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Nonlinear modeling. AD biomarkers exhibit nonlinear
time courses across disease progression (Bateman et al.,
2012; Jack et al., 2010; Kinnunen et al., 2018). Proposed biomarker models suggest nonlinear time courses with sigmoidal shape ( Jack et al., 2010). The sigmoid transition time
(i.e., when peak rate-of-change occurs) varies based on the
biomarker. We investigated a sigmoidal shape of the global
FC signature for MC participants to estimate transition
times. An unweighted moving average of the global FC signature for MC participants was computed as a function of
EYO using bin sizes of –5 years to capture long-term trends.
A model of staggered logistic decline evaluated the relationship between the global FC signature and EYO (t) for MC
participants:


1
1
global FC signature = A

,
1 þ e  rðt  t1 Þ 1 þ e  rðt  t2 Þ

where A is carrying capacity, r is growth rate, and t1 and t2
are transition times. Here the carrying capacity describes
the maximum FC that can be sustained. The growth rates
and carrying capacities for both curves were constrained
by goodness-of-fit using the Shapiro–Wilks test of normality
on the residuals (Shapiro and Wilk, 1965). Nonlinear leastsquares regression was performed using the ‘‘nlm’’ function
in R (Dennis and Schnabel., 1983; R Core Team, 2017;
Schnabel et al., 1985). The Akaike Information Criterion
(AIC), Bayesian Information Criterion (BIC), and Levene’s
test were used to further evaluate model performance by
comparing with polynomial models (i.e., linear, quadratic,
and cubic) (Levene, 1960).
Association between global FC signature
and AD biomarkers

Associations were computed between a participant’s
global FC signature and A/T/(N) biomarkers, including
CSF biomarkers (log-transformed Ab1–42 [A1], p-tau181
[T1], and total-tau [N1]), PET molecular biomarkers (PiB
mean cortical SUVR [A2] and FDG uptake in the precuneus
[N2]), and a structural MRI biomarker (hippocampal volume
[N3]). To investigate the relationship between global FC signature and AD biomarkers while adjusting for mediating associations, the partial correlation matrix (P) was computed
by matrix inversion of the correlation matrix (R) such that
the partial correlation between the i-th and j-th biomarkers
was defined as follows:
sij
pij =  pﬃﬃﬃﬃﬃﬃﬃﬃ ,
sii sjj
where sij were the elements of the inverted correlation matrix
S = R  1.
Results
Demographics

Cross-sectional FC data were obtained for NC (n = 104)
and MC (n = 171) participants. NC individuals were older
than MC CDR 0 ( p < 0.05) participants, but younger than
MC CDR >0 ( p < 0.05) participants. Similarly, MC CDR 0
participants were younger than MC CDR >0 participants
( p < 0.05) (Table 1).
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Table 1. Demographic and Clinical Comparison
of Non- and Mutation Carrier Groups

Downloaded by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE St. Louis E-PACKAGE from www.liebertpub.com at 05/19/21. For personal use only.

n
Age: M (SD)
Gender (M/F)
CDR (0/0.5/ > 0.5)

NC

MC

104
40.2 (11.3)
41/63
104/0/0

171
39.4 (11.3)
74/97
99/46/26

CDR, clinical dementia rating; MC, mutation carrier; NC, noncarrier.

Spatial topology of the global FC signature of ADAD

We observed a global FC signature of ADAD, with
strong contributions from both intra- and internetwork
connections that spanned multiple RSNs (Fig. 1). This
global FC signature was influenced by both positive and
negative correlations and, for visual clarity, was separated
along the diagonal based on the direction of influence on
the global FC signature. Networks whose positive correlations had a strong influence included the SM, SMlat, CO,

AUD, VIS, and MEM (intranetwork). Networks whose
negative correlations had a strong negative influence included the FP, MEM (internetwork), DAN, and DMN.
The global FC signature associates
with markers of disease progression

The global FC signature decreased with pathology. We
observed that the global FC signature was significantly decreased in MC (yellow) compared with NC (gray) participants (Fig. 2A). When MC participants were further
differentiated by CDR status, the global FC signature significantly decreased in MC CDR >0 (Fig. 2A, red; p < 0.05)
compared with either MC CDR 0 (green) or NC (gray) participants. NC and MC CDR 0 participants were not significantly different ( p > 0.05). For MC participants, a negative
association was observed between mutation EYO and the
global FC signature (Spearman’s q = 0.33, p = 1.2e-05;
Fig. 2B). The association between the global FC signature
and EYO remained significant after controlling for CDR status. We also observed that the global FC signature predicted,
on average, 5 to 18 percent more variance for the actual EYO
than internetwork RSN values (Fig. 2C).

FIG. 2. (A) The global FC signature as a function of mutation status, CDR, and EYO. (A) Violin and box plots of the global
FC signature for NC (gray) and MC (yellow), MC CDR 0 (green), and MC CDR >0 (red) participants. NC had a higher global
FC signature compared with MC. MC CDR >0 had significant decreases in the global FC signature compared with NC and
MC CDR 0 participants. A black bar represents a significant group difference. (B) Line plot showing the association between
global FC signature and mutation EYO for MC participants. The global FC signature was associated with EYO in MC
( p < 0.05). The dashed line (black) is the mean global FC signature in NC participants, and the dark gray band is the confidence interval defined as two standard errors of the mean. (C) Coefficient of determination (R2) for the global FC signature
and the intranetwork values of 12 RSNs. The length of the vertical bar represents the strength of that FC value for predicting
EYO. (D) The global FC signature for MC individuals exhibits a biphasic behavior with regard to mutation EYO in –5-year
bins. When the global FC signature was fit to the bin means (yellow curve), two logistic curves were observed (magenta and
cyan). A two-stage process was observed, with early and late changes seen in the global FC signature. CDR, clinical dementia
rating; EYO, expected years to symptom onset; MC, mutation carrier; NC, noncarrier. Color images are available online.
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Nonlinear EYO modeling of the global FC signature

With regard to EYO, the global FC signature varied nonlinearly across the time course of the disease (Fig. 2D). This
was consistent with a dual-logistic behavior model characterized by two transition times that were offset by *17
years (Shapiro–Wilk’s W = 0.97, p = 0.28). This nonlinear
model (AIC = 161, BIC = 153) performed significantly
better than the first-order (AIC = 128, BIC = 123),
second-order (AIC = 128, BIC = 121), and third-order
(AIC = 126, BIC = 118) polynomial models (Levene’s
F = 4.04, p = 0.002), and suggested a two-stage process.
The global FC signature was elevated early in the disease
time course (EYO < 16.7 years) in MC followed by a period that resembled control levels until further decreasing
near the estimated time of symptom onset (EYO = 0.5 years).
Association between global FC signature and biomarkers

Strong associations were observed between CSF total tau
and CSF p-tau181 (r = 0.86, p < 10E-16), mean cortical PiB
SUVR and CSF total tau (r = 0.53, p = 1.7E-9), mean cortical
PiB SUVR and CSF p-tau181 (r = 0.65, p = 2.2E-16), and precuneus PET FDG and hippocampal volume (r = 0.53,
p = 1.6E-09).
Strong associations were observed between the global
FC signature and several AD biomarkers (Fig. 3B, left).
The global FC signature was compared with each AD biomarker classified according to the amyloid (A), tau (T),
and neurodegeneration (N) framework (Fig. 3A). With
regard to A criteria, the global FC signature was negatively associated with amyloid deposition as measured
by mean cortical PiB SUVR ( p = 0.03), and was positively
correlated with CSF Ab1–42 ( p = 0.007). With regard to T
criteria, the global FC signature was negatively associated
with CSF p-tau181 ( p = 0.009). With regard to (N) criteria,
the global FC signature was negatively associated with
CSF total tau ( p = 0.02), and positively associated with
both precuneus PET FDG ( p = 0.002) and hippocampal
volume ( p = 0.001). For each of these biomarkers, a
worse global FC signature score was associated with
greater pathology.
To investigate the strength of the direct pathological relationship between any two biomarkers (including the
global FC signature), we controlled for potential mediating
effects of general pathological decline. Specifically, an unbiased model was computed using a partial correlation matrix that controlled for other biomarkers (Fig. 3B, middle).
In this unbiased model, no assumption of a specific temporal sequence of biomarkers was included. This network
model strongly differentiated AT(N) biomarkers and agreed
with previously hypothesized trajectories with amyloid
measures strongly associating with each (A1 and A2), measure of tau (T1) strongly tied to neurodegeneration (N1), as
well as measures of neurodegeneration group together (N1,
N2, and N3) (Fig. 3B, right). In this model, the global FC
signature most strongly associated with CSF Ab 1–42 (A1)
and hippocampal volume (N3). These results provide further evidence of a two-stage process concerning the global
FC signature with changes associating with early and late
biomarkers. Moreover, these results suggest that each
stage may be associated with changes in either amyloid accumulation or volumetrics.
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Discussion

These results provide evidence that disruption of multiple functionally connected brain networks occurs in
ADAD MC that is both stage dependent (asymptomatic versus symptomatic) and state dependent (biomarker status).
Disruption of the global FC signature was greatest in symptomatic MC carriers. This indicates that changes in the
global FC signature are tightly coupled with clinical presentation. However, even after adjusting for symptom severity
using CDR, disruption of the global FC signature was significantly associated with disease progression, as measured
by EYO. Furthermore, the global FC signature was, on average, a better predictor of EYO compared with intranetwork values of individual RSNs. Changes in the global
FC signature were also associated with pathological biomarkers classified using the AT(N) framework for designating temporal progression of AD. Two independent methods
showed that disruption of the global FC signature (1) occurred primarily during early (EYO * 17) and late
(EYO *0) stages, and (2) was associated with early-stage
(CSF Ab1–42) and late-stage (hippocampal atrophy) biomarker changes. Taken together, these results suggest that
the global FC signature may be sensitive to distinct processes affecting synaptic activity: Ab accumulation early
on in disease progression and neurodegeneration during
later stages.
Our results are consistent with previous FC studies that investigated the disruption of specific RSNs in ADAD, but also
shed new light on patterned changes across the entire spatial
topography. Previous studies have primarily focused on FC
changes within a single network. Changes have typically
focused on the DMN, as this network has been associated
with amyloid deposition (Buckner et al., 2009; Greicius
et al., 2004) and is one of the largest networks with regard
to the overall size in the brain (Greicius et al., 2003). In
our current analysis, a global FC pattern of disruption was
observed that included both intra and internetwork brain connections. These results suggest that prior studies primarily
focusing on changes within a single network may overlook
important changes seen within not only a network but also
changes between networks. Our analysis is a logical progression from previous work that demonstrated that intra- and
internetwork brain connections across multiple networks
were affected with progression to cognitive impairment in
ADAD (Thomas et al., 2014). In our current analysis,
RSNs that associated with cognitive impairment included
cognitive processing networks, including MEM, FP, DAN,
and DMN, as well as sensory cortical regions such as the
SM, SM-lat, VIS, and AUD. Cognitive processing regions
that have been associated with the changes in pathological
biomarkers, such as amyloid and tau accumulation and volume loss, and disruption of FC in these regions, may be associated with positivity of one or more biomarkers.
Interestingly, neither FC nor pathological changes are typically observed in primary sensory regions. These results suggest that the FC disruption observed may be a precursor to
subsequent pathology.
Disruption was greatest for symptomatic mutation carriers
(MC CDR >0) compared with mutation NC. Our data
showed that the greatest changes in the FC signature occurred for the symptomatic disease stage based on clinical
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FIG. 3. The global FC signature as a function of Alzheimer disease (AD) biomarkers in mutation-positive (MC) individuals. Analyses investigated amyloid (A; green), Tau (T; purple), and neurodegenerative (N; orange) biomarkers. Scatter plots
show that the global FC signature was (A) positively associated with CSF Ab1–42, negatively associated with mean PiB
SUVR, negatively associated with CSF p-tau181 and total tau, and positively associated with both precuneus FDG uptake
and hippocampal volume. (B) The correlation matrix of all biomarkers, including global FC signature (left), was inverted
to compute the partial correlation matrix (middle). Network map of relationships was plotted among the global FC signature,
and AD biomarkers based on the partial correlation matrix. The fully (light edges) and minimally (dark edges) connected
graphs are shown. All associations were corrected for age. CSF, cerebrospinal fluid; FDG, 18F-fluorodeoxyglucose; PiB,
Pittsburgh compound B; p-tau181, phosphorylated tau181; SUVR, standardized uptake value ratios. Color images are available
online.

staging and genetic profile. Specifically, our data showed that
50% of the MC symptomatic cohort overlapped with the
worst 25% of the asymptomatic MC cohort. This degree of
overlap can be attributed to the classification scheme that
is based on subjective responses during the clinical interview. This sensitivity to symptom manifestation bolsters
the capability of this imaging marker as a tool for disease
conversion. Future studies may assess the capability of an
FC signature to redefine group classification to better identify
individuals on the cusp of conversion.

Our results are consistent with previous FC studies that
investigated disease progression using linear modeling,
but also provide new insight regarding the time line of FC disruption. Linear modeling of disease progression suggests that
FC disruption begins before the onset of symptoms. Consistent with previous results, we used a linear model and observed that FC disruption in certain RSNs occurred *5
years before expected symptom inset (EYO 5) (Chhatwal
et al., 2013). However, previous reports show that AD biomarkers exhibit nonlinear time courses across disease stages
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(Dubois et al., 2016; Jack et al., 2010). In an updated model of
disease progression, we observed that the global FC signature
also exhibited a nonlinear time course that was consistent with
proposed biomarker models ( Jack et al., 2010). Specifically,
disruption of the global FC signature was marked by two dramatic changes that occurred during very early (*17 EYO)
and late (*0 EYO) disease stages in AD progression. The
time period leading up to the initial decrease of the global
FC signature could suggest a very early period of hyperconnectivity (Schultz et al., 2017). The production of Ab has
been linked to increased synaptic activity that can manifest
as nonconvulsive seizures that are present before cognitive
symptoms (Amatniek et al., 2006; Cirrito et al., 2005; Jack
et al., 2010). FC hyperactivity has also been observed in
LOAD particularly in areas with advanced Ab accumulation
(Ovsepian and O’Leary, 2016). It remains unclear whether
this hyperactivity is detrimental due to synaptic excitotoxicity
or compensatory due to increased pathological burden (Palop
and Mucke, 2010). Our data suggest that this hyperactivity in
FC may be a compensatory mechanism to preserve cognitive
stability provided this observed state was years before symptom onset (Su et al., 2015). However, prolonged hyperactivity
can lead to cognitive deficits and overall loss in connectivity
strength (Thomas et al., 2014). This coincides with the second
sharp decrease in the global FC signature that occurred at
EYO = 0. This is consistent with evidence from MRI studies
that show volume loss accelerates near EYO = 0 (Ewers
et al., 2011). Together our data show an overall pattern that
initiates with a decline from a hyperactive state that briefly
returns to baseline levels before declining near symptom
onset. These results suggest a dual-pathology process that reflects biological changes in the absence of behavioral changes.
Understanding these distinct processes is clinically important
for treatment intervention as individuals may respond differently based on their point on these curves.
The ability to characterize changes in a global FC signature
during pre-clinical stages of AD was further supported by a
separate linear model that focused on AT(N) biomarkers. A
number of studies focusing on pathological biomarkers have
proposed an AT(N) sequence in LOAD (Schnabel et al.,
1985). Our model for ADAD was given no a priori assumptions concerning the sequence of biomarker events, except
that the sequence should be consistent for participants. Despite
our assumption of no specific temporal sequence of biomarker
progression, our work further supports that ADAD and LOAD
have similar temporal patterns for AD biomarkers regardless of
the age of onset or genetic association (Schultz et al., 2017).
Furthermore, we found that disruption of the global FC signature was preferentially associated with both CSF Ab1–42 and
hippocampal atrophy, biomarkers that characterize pathological changes occurring during the early and late stages of AD,
respectively. This suggests that genetic mutations set in motion
a time line of AT(N) biomarker changes with brain amyloidosis (possibly with certain soluble amyloid peptides proposed
to be more closely associated with neuronal excitotoxicity)
(A) followed by tauopathy (T) and eventually reduced glucose
metabolism and brain volumetrics (N) (Bateman et al., 2011;
Behzadi et al., 2007; Shapiro and Wilk, 1965).
Our results contribute to the understanding of how, in AD
etiology, changes in global network functionality precipitate
eventual short-term episodic memory deficits, the hallmark
of AD. Based on these results it may be possible to use the
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global FC signature as a marker of underlying neuronal response to trials that introduce anti-Ab therapies very early
in the disease. Advantages for FC as an outcome measure
in clinical trials include lack of radiation unlike PET biomarkers, and being less invasive than a lumbar puncture
for CSF. Further studies should also look at changes in comparison with LOAD. Longitudinal studies of changes in FC
in this cohort are needed to more robustly evaluate the nature
of neuronal dysfunction with disease progression.
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